NCT02087865View on ClinicalTrials.gov

Effects of Donepezil HCL on Task-Activated fMRI Brain Activation in Healthy Older Adults at Genetic Risk for Alzheimer's Disease

PHASE4CompletedINTERVENTIONAL
Enrollment

89

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

December 20, 2021

Study Completion Date

December 20, 2021

Conditions
Genetic Risk for Alzheimer's Disease
Interventions
DRUG

donepezil HCL

DRUG

Placebo

Trial Locations (1)

44195

Cleveland Clinic Center for Brain Health, Cleveland

All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

lead

The Cleveland Clinic

OTHER

NCT02087865 - Effects of Donepezil HCL on Task-Activated fMRI Brain Activation in Healthy Older Adults at Genetic Risk for Alzheimer's Disease | Biotech Hunter | Biotech Hunter